COMPARATIVE BIOAVAILABILITY (BIOEQUIVALENCE) STUDY FOR FIXED DOSE COMBINATION TABLET CONTAINING AMLODIPINE, VALSARTAN, AND HYDROCHLOROTHIAZIDE USING A NEWLY DEVELOPED HPLC-MS/MS METHOD
Keywords:
Amlodipine, Valsartan, Hydrochlorothiazide, Pharmacokinetics, Bioequivalence, HPLC-MSMSAbstract
Objective: The aim of the study was to evaluate the bioequivalence between a newly developed generic tablet containing fixed-dose combination of amlodipine besylate, valsartan and hydrochlorothiazide (10/160/25 mg), and the reference brand product Exforge HCT® tablet; using a newly developed HPLC-MS/MS method for simultaneous determination of these drugs in human plasma.
Methods: The brand (reference) and the test (generic) products were administered to thirty-nine healthy subjects. A fasting, laboratory blind, single-dose, two-treatment, two-period, two-sequence, randomized crossover design was conducted with 14 d washout period between dosing. Serial blood samples were withdrawn from each subject immediately before dosing (zero time), and then at 0.33, 0.66, 1.0, 1.33, 1.66, 2.0, 2.5, 3.0, 3.5, 4.0, 5.0, 6.0, 6.5, 7.0, 7.5, 8.0, 8.5, 9.0, 9.5, 10, 11, 12, 14, 16, 24, 48 and eventually at 72 h post dosing. Plasma samples were analyzed for simultaneous determination of amlodipine, valsartan and hydrochlorothiazide by a newly developed HPLC coupled with MS/MS detector. The linearity of the method was established for plasma concentration ranges of 0.2-12 ng/ml, 50-8000 ng/ml, and 2-250 ng/ml for amlodipine, valsartan, and hydrochlorothiazide, respectively.
Results: Plasma concentration-time data of each individual were analyzed by non-compartmental method to measure the pharmacokinetics parameters; Cmax, Tmax, AUC0-t, AUC0-Â¥, lZ, T1/2. For amlodipine truncated AUC72hr was calculated. The 90% confidence interval for the pharmacokinetic parameters used for bioequivalence evaluation (Cmax and AUC) for amlodipine, valsartan, and hydrochlorothiazide were well within FDA acceptable ranges of 80-125%.
Conclusion: It is concluded that the newly devolved generic product is bioequivalent with the brand product Exforge HCT® tablet. Thus, both products are clinically interchangeable.
Keywords: Amlodipine, Valsartan, Hydrochlorothiazide, Pharmacokinetics, Bioequivalence, HPLC-MS/MS
Downloads
References
Exforge HCT® tablet product information, produced by Novartis Switzerland, distributed by Novartis Pharmaceuticals Corporation East Hanover, New Jersey 07936 Revised; 2015.
Karpov Y, Dongre N, Vigdorchik A, Sastravaha K. Amlodipine/valsartan single-pill combination: a prospective, observational evaluation of the real-life safety and effectiveness in the routine treatment of hypertension. Adv Ther 2012;29:134-47.
Malesker MA, Hilleman DE. Comparison of amlodipine/ valsartan fixed-dose combination therapy and conventional therapy. Manag Care 2010;19:36-42.
Neutel JM, Smith DH. Hypertension management: rationale for triple therapy based on mechanisms of action. Cardiovasc Ther 2013;31:251-8.
de la Sierra A, Barrios V. Blood pressure control with angiotensin receptor blocker-based three-drug combinations: key trials. Adv Ther 2012;29:401-15.
Lacourcière Y, Crikelair N, Glazer RD, Yen J, Calhoun DA. 24-Hour ambulatory blood pressure control with triple-therapy amlodipine, valsartan and hydrochlorothiazide in patients with moderate to severe hypertension. J Hum Hypertens 2011;25:615-22.
Lancellotti P. Medication of the month. Exforge HCT: combination of amlodipine besylate, valsartan and hydro-chlorothiazide in a single tablet. Rev Med Liege 2010;65:471-5.
Doménech M, Coca A. Role of triple fixed combination valsartan, amlodipine and hydro-chlorothiazide in controlling blood pressure. J Patient Prefer Adherence 2010;13:105-13.
Calhoun DA, Crikelair NA, Yen J, Glazer RD. Amlodipine/ valsartan/hydrochlorothiazide triple combination therapy in moderate/severe hypertension: Secondary analyses evaluating efficacy and safety. Adv Ther 2009;26:1012-23.
Deeks ED. Amlodipine/valsartan/hydrochlorothiazide: fixed-dose combination in hypertension. Am J Cardiovasc Drugs 2009;9:411-8.
Tung YC, Lin YS, Wu LS, Chang CJ, Chu PH. Clinical outcomes and healthcare costs in hypertensive patients treated with a fixed-dose combination of amlodipine/valsartan. J Clin Hypertens 2015;17:51-8.
Xie L, Frech-Tamas F, Marrett E, Baser O. A medication adherence and persistence comparison of hypertensive patients treated with single-double-and triple-pill combination therapy. Curr Med Res Opin 2014;30:2415-22.
Bhad P, Ayalasomayajula S, Karan R, Leon S, Riviere GJ, Sunkara G, et al. Evaluation of pharmacokinetic interactions between amlodipine, valsartan, and hydrochlorothiazide in patients with hypertension. J Clin Pharmacol 2011;51:933-42.
Hedaya MA, Helmy SA. Pharmacokinetic interactions of valsartan and hydrochlorothiazide: an open-label, randomized, 4-period crossover study in healthy Egyptian male volunteers. Clin Ther 2013;35:846-61.
Noh YH, Lim HS, Kim MJ, Kim YH, Choi HY, Sung HR, et al. Pharmacokinetic interaction of telmisartan with s-amlodipine: an open-label, two-period crossover study in healthy korean male volunteers. Clin Ther 2012;34:1625-35.
Rohatagi S, Lee J, Shenouda M, Haworth S, Bathala MS, Allison M, et al. Pharmacokinetics of amlodipine and olmesartan medoxomil in separate dosage forms and as a fixed-dose combination. J Clin Pharmacol 2008;48:1309-22.
Jung JA, Lee SY, Kim JR, Ko JW, Jang SB, Nam SY, et al. A pharmacokinetic and pharmacodynamic drug interaction between rosuvastatin and valsartan in healthy subjects. Drug Des Dev Ther 2015;9:745-52.
Lee J, Lee H, Jang K, Lim KS, Shin D, Yu KS. Evaluation of the pharmacokinetic and pharmacodynamic drug interactions between cilnidipine and valsartan, in healthy volunteers. Drug Des Dev Ther 2014;8:1781-8.
Jung JA, Noh YH, Jin S, Kim MJ, Kim YH, Jung JA, et al. Pharmacokinetic interaction between pitavastatin and valsartan: a randomized, open-labeled crossover study in healthy male korean volunteers. Clin Ther 2012;34:958-65.
Kasichayanula S, Chang M, Liu X, Shyu WC, Griffen SC, LaCreta FP, et al. Lack of pharmacokinetic interactions between dapagliflozin and simvastatin, valsartan, warfarin or digoxin. Adv Ther 2012;29:163-77.
Liu DY, Jiang J, Wang CG, Zhang JY, Hu P. Pharmacokinetics and tolerability of olmesartan medoxomil plus hydro-chlorothiazide combination in healthy Chinese subjects: drug-drug interaction, bioequivalence, and accumulation. Int J Clin Pharmacol Ther 2014;52:321-7.
Kreutz R, Bolbrinker J, Huber M. Pharmaco-kinetics of olmesartan medoxomil plus hydro-chlorothiazide combination in healthy subjects. Clin Drug Invest 2006;26:29-34.
Norvasc® (Amlodipine besylate) monograph, Pfizer, Canada, Inc. 17 300 Trans-Canada Highway Kirkland, Quebec H9J 2M5, Submission Control No: 177714, Date of Revision; 2015.
van der Vossen AC, van der Velde I, van den Meiracker AH, van der Nagel BC, Koch BC, Vulto AG, et al. Bioequivalence study of an extemporaneously prepared oral solution of amlodipine suitable for use in pediatric patients compared to commercial tablets. Int J Clin Pharmacol Ther 2016;54:65-72.
Lee SY, Kim JR, Jung JA, Huh W, Bahng MY, Ko JW. Bioequivalence evaluation of two amlodipine salts, besylate and orotate, each in a fixed-dose combination with olmesartan in healthy subjects. Drug Des Dev Ther 2015;9:2811-7.
Jaafar JI. Bioequivalence and pharmacokinetics of two formulations of amlodipine tablets in healthy subjects. Iraqi J Pharm Sci 2014;23:60-7.
Jangala H, Vats P, Khuroo AH, Monif T. Development and validation of a LC-MS/MS method for the simultaneous estimation of amlodipine and valsartan in human plasma: Application to a bioequivalence study. Sci Pharm 2014;82:585-600.
Choi HY, Kim YH, Kim MJ, Noh YH, Lee SH, Bae KS, et al. Pharmacokinetics, tolerability, and safety of the single oral administration of AGSAV301 vs exforge: a randomized crossover study of healthy male volunteers. Am J Cardiovasc Drugs 2014;14:63-72.
Kim Y, Son M, Lee D, Roh H, Son H, Chae D, et al. Pharmacokinetic comparison of 2 fixed dose combination tablets of amlodipine and valsartan in healthy male Korean volunteers: a randomized, open-label, 2-period, single-dose, crossover study. Clin Ther 2013;35:934-40.
Mascoli V, Kuruganti U, Bapuji AT, Wang R, Damle B. Pharmacokinetics of a novel orodispersible tablet of amlodipine in healthy subjects. J Bioequivalence Bioavailability 2013;5:76-9.
Mustafa SK, Agata B, Michał S, Selma Ş. Bioavailability file: amlodipine scientific review. FABAD J Pharm Sci 2011;36:207-22.
Liu Y, Jia J, Liu G, Li S, Lu C, Liu Y, et al. Pharmacokinetics and bioequivalence evaluation of two formulations of 10-mg amlodipine besylate: an open-label, single-dose, randomized, two-way crossover study in healthy Chinese male volunteers. Clin Ther 2009;31:777-83.
Effi S, Sukmayadi, Danong AY, Lucia RH, Gunawan H, Iwan DS, et al. Bioequivalence of two amlodipine tablet formulations. May Kedokt Indom 2008;58:41-6.
Sailer R, Arnold P, ErenmemiÅŸoÄŸlu A, Martin W, Tamur U, Kanzik I, et al. Pharmacokinetics and bioequivalence study of a generic amlodipine tablet formulation in healthy male volunteers. Arzneimittelforschung 2007;57:462-6.
Setiawati E, Sukmayadi, Yunaidi DA, Handayani LR, Harinanto G, Santoso ID, et al. Comparative bioavailability of two amlodipine formulation in healthy volunteers. Arzneimittelforschung 2007;57:467-71.
Park JY, Kim KA, Park PW, Lee OJ, Kim JS, Lee GH, et al. Comparative pharmacokinetic and pharmacodynamic characteristics of amlodipine besylate and amlodipine nicotinate in healthy subjects. Int J Clin Pharmacol Ther 2006;44:641-7.
Rojanasthien N, Teekachunhatean S, Jakob K, Gaupp M, Arnold P, Chaichana N, et al. Bioequivalence study of generic amlodipine in healthy Thai male volunteers. Int J Clin Pharmacol Ther 2004;42:330-5.
Lyszkiewicz DA, Levichek Z, Kozer E, Yagev Y, Moretti M, Hard M, et al. Bioavailability of a pediatric amlodipine suspension. Pediatr Nephrol 2003;18:675-8.
Kim JE, Ki MH, Yoon IS, Cho HJ, Kim RS, Tae Kim G, et al. Pharmacokinetic properties and bioequivalence of 2 formulations of valsartan 160-mg tablets: A randomized, single-dose, 2-period crossover study in healthy Korean male volunteers. Clin Ther 2014;36:273-9.
Zaid AN, Cortesi R, Qaddomi A, Khammash S. Formulation and bioequivalence of two valsartan tablet after a single oral administration. Sci Pharm 2011;79:123-35.
Diovan® (Valsartan) FDA prescribing information, Last reviewed on Rx List; 2013.
Li H, Wang Y, Jiang Y, Tang Y, Wang J, Zhao L, et al. A liquid chromatography/tandem mass spectrometry method for the simultaneous quantification of valsartan and hydrochlorothiazide in human plasma. J Chromatogr B: Anal Technol Biomed Life Sci 2007;852:436-42.
Hydrochlorothiazide FDA prescribing information, Westminster Pharmaceuticals, LLC; 2016.
Jiang J, Tian L, Huang Y, Xie S, Xu L, Liu H, et al. Pharmacokinetic profiles of hydrochlorothiazide alone and in combination with benazepril or valsartan in healthy Chinese volunteers: evaluation of the potential interaction. Int J Clin Pharmacol Ther 2011;49:756-64.
Lakshmi B, Krishna KR, Jayaveera KN. Development and validation of RP-HPLC method for determination of Amlodipine. Int J Appl Biol Pharm Technol 2015;6:225-31.
Lotfy HM, Hegazy MA, Mowaka S, Mohamed EH. Novel spectrophotometric methods for simultaneous determination of Amlodipine, Valsartan and Hydrochlorothiazide in their ternary mixture. Spectrochim Acta Part A 2015;140:495-508.
Ebeid W, Salim M, Elkady E, Elzahr A, El-Bagary R, Patonay G. Simultaneous
determination of valsartan, amlodipine besylate and hydrochlorothiazide using capillary zone electrophoresis (CZE). Pharmazie 2015;70:368-73.
Dondeti MR, Putchakayala PR, Ramachandran D. Stability indicating HPLC method for simultaneous estimation of hydrochlorothiazide, amlodipine and valsartan in pharmaceutical dosage from. World J Pharm Sci 2014;2:1830-6.
Rasha A, Tarek S, Fawzy A, Sohila M. Validated HPTLC methods for determination of some selected antihypertensive mixtures in their combined dosage forms. Bull Faculty Pharm Cairo University 2014;52:225–37.
Sharma M, Kothari C, Sherikar O, Mehta P. Concurrent estimation of amlodipine besylate, hydrochlorothiazide and valsartan by RP-HPLC, HPTLC and UV-spectrophotometry. Chromatogr Sci 2014;52:27-35.
Nitesh Maheshwari. Validated reverse phase high performance liquid chromatography method for simultaneous estimation of valsartan potassium and amlodipine besylate in tablet dosage form. Int J Drug Dev Res 2013;5:237-44.
Darwish HW, Hassan SA, Salem MY, El-Zeany BA. Comparative study between derivative spectrophotometry and multivariate calibration as analytical tools applied for the simultaneous quantitation of amlodipine, valsartan and hydrochlorothiazide. Spectrochim Acta Part A 2013;113:215-23.
Hany W, Said A, Maissa Y, Badr A. Sequential spectrophotometric method for the simultaneous determination of amlodipine, valsartan, and hydrochlorothiazide in coformulated tablets. Int J Spectrosc 2013;1-8. Doi.org/10.1155/2013/273102. [Article in Press]
Tadeusz I, Anna G, Paulina M, Ewelina R. New HPLC method with experimental design and fluorescence detection for analytical study of antihypertensive mixture, amlodipine and valsartan. Am J Anal Chem 2013;4:17-23.
Antil P, Kaushik D, Jain G, Srinivas KS, Thakur I. UPLC method for simultaneous determination of valsartan & hydrochlorothiazide in drug products. J Chromat Separation Techniq 2013;4:182.
Li H, Wang Y, Jiang Y, Tang Y, Wang J, Zhao L, et al. A liquid chromatography/
tandem mass spectrometry method for the simultaneous quantification of valsartan and hydrochlorothiazide in human plasma. J Chromatogr B: Anal Technol Biomed Life Sci 2007;852:436-42.
Hai-Yan Fu, He-Dong Li, Chuang Ni, Tian-Ming Yang, Yao Fan, Hao Zhang, et al. Micellar enhanced three-dimensional excitation-emission matrix fluorescence for rapid determination of antihypertensives in human plasma with aid of second-order calibration methods. J Spectrosc 2015;1-11. Doi.org/10.1155/2015/681320. [Article in Press]
Yucel K, Murat O. Spectrofluorimetric determination of amlodipine in human plasma without derivatization. Braz J Pharm Sci 2012;4. Doi.org/10.1590/S1984-82502012000400016. [Article in Press]
Shentu J, Fu L, Zhou H, Hu XJ, Liu J, Chen J, et al. Determination of amlodipine
in human plasma using automated online solid-phase extraction HPLC-tandem mass spectrometry: application to a bioequivalence study of Chinese volunteers. J Pharm Biomed Anal 2012;70:614-8.
Guidance For Industry. Bioavailability and Bioequivalence Studies for Orally Administered Drug Products–General Considerations. U. S. Department of Health and Human Services. Food and Drug Administration. Center for Drug Evaluation and Research (CDER); 2003.
Guidance For Industry. Bioequivalence Studies with Pharmacokinetic Endpoints for Drugs Submitted Under an ANDA. U. S. Department of Health and Human Services. Food and Drug Administration. Center for Drug Evaluation and Research (CDER). Draft Guidance; 2013.
European Medicines Agency (EMEA). Committee For Medicinal Products For Human Use (CHMP). Guidelines On The Investigation of Bioequivalence; 2010.
Shein-Chung C, Jen-Pei L. Design and analysis of bioavailability and bioequivalence studies. Second Edition. Revised and Expanded. Marcel Dekker, Inc: New York; 2000.
Nidhal KM. Inquiries for setting up bioequivalence center with fast track in the main aspects of biopharmaceutics and pharmacokinetics. First edition. Iraq: Dar alebtikar publishers; 2013.
Guidance For Industry. Bioanalytical Method Validation For Human Studies. U. S. Department of Health and Human Services. Food and Drug Administration. Center for Drug Evaluation and Research (CDER); 2001.
Latest WMA Declaration of Helsinki-Ethical Principles for Medical Research Involving Human Subjects; 2013.
ICH Guideline for Good Clinical Practice (GCP). E6; 1996.
Shargel L, Andrew Yu. Applied biopharmaceutics and pharmacokinetics. Sixth Edition. Appleton and Lange USA; 2012.
Guidance For Industry. Statistical Approaches to Establishing Bioequivalence. U. S. Department of Health and Human Services. Food and drug administration. Center for Drug Evaluation and Research (CDER); 2001.